Simulations Plus' ( SLP ) share price plummeted after the company reported preliminary Q3 FY25 results that fell well short of expectations. While soft biopharma market conditions and Simulations Plus' relatively large services business mean that current weakness is not surprising, the companyRichard Durant is the leader of Narweena, an asset manager focused on finding market dislocations that are the result of a poor understanding of a businesses long-term prospects. Narweena believes that excess risk adju ...